Press Room


    Press Release - June 26, 2006

    Justin Leushner Appointed to Board of Directors

    Kelowna, B.C. -- To facilitate the progress of its diabetes product development project, Pheromone Sciences Corp. ("Pheromone") is pleased to announce that Mr. Justin Leushner of London, Ontario, has been named President of the Company, effective immediately. In addition, Mr. Leushner has been appointed to the Board of Directors. He is currently the manager of the Islet Transplant Program at the London Health Sciences Centre's ("LHSC") world renowned Multi-Organ Transplant Program. His role as President will include primary responsibility for monitoring the progress of Pheromone's diabetes research project being conducted at the LHSC's facilities. The project is Pheromone's primary research focus and is being funded by the Company's recently completed $3.2 million financing.

    "Mr. Leushner brings with him a thorough knowledge of the research goals and possibilities of the technology we will be developing," said Pheromone Chief Executive Officer Dev Randhawa. "His balance of business acumen and scientific understanding makes him an excellent representative of our company's profile."

    Mr. Leushner is also President and 50 percent shareholder in Sertonex Inc., a private London Ontario based company Pheromone is acquiring in stages as a result of Pheromone exercising its option under a recent joint venture and financing agreement with Sertonex and Sertoli Technologies Inc. of Tucson, Arizona. Under the terms of that agreement, Sertonex and Sertoli Technologies both have the right to nominate one member to Pheromone's board.

    About Justin Leushner Mr. Leushner has had an extensive and diverse business career in the life sciences and biotechnology industries. He has participated in many entrepreneurial start-up companies, which have included consumer products, new technologies and biotechnology. He was also responsible for developing a national molecular diagnostics program for MDS Inc., Canada's largest life science's company, and served as a business analyst and portfolio advisor to the Canadian Medical Discoveries Fund. In 2004, Mr. Leushner co-founded Sertonex Inc. with Dr. David White, now Pheromone's primary researcher on the diabetes project.

    An MBA graduate of the University of Western Ontario's Ivey School of Business, Mr. Leushner also holds a B.Sc. in Cell Physiology/Genetics from the University of British Columbia and numerous technical designations in Forensic Science and Molecular Biology.

    About the Research Project Pheromone's research project is intended to lead to a procedure approved by the U.S. Food and Drug Administration for treating diabetes by transplanting into humans a device containing pig islets and Sertoli cells. The islet cells produce insulin almost identical to that found in humans, and the Sertoli cells naturally protect the islet cells from attack by the body's immune system. The research is based on several proof-of-concept experiments completed by Dr. White and others.

    Pheromone Sciences Corp. is a biotechnology research and development company focused on commercializing medical technologies.


    "Dev Randhawa"

    Dev Randhawa, President

    For further information contact:

    TEL: (250) 868-8177 Mr. Phil Morehouse FAX: (250) 868-8493 Pheromone Sciences Corp.

    TEL: (519) 639-7867 Mr. Justin Leushner FAX: (519) 858-5142 Sertonex Inc.

    TEL: (520) 748-4458 Ms. Jan McCoy Hutchinson FAX: (520) 748-0025 Sertoli Technologies Inc.


    Press Releases from:

    2018 2017 2016 2015 2014 2013 2012

    2011 2010 2009 2008 2007 2006 2005

    2004 2003 2002 2001 2000 1999

    Featured News

    2014, January 22

    Sernova’s Disruptive Regenerative Medicine Technologies Set to Improve the Treatment of Chronic Diseases While Reducing Healthcare Costs


    2012, July 11

    Sernova Corp. developing a tiered approach to the treatment of diabetes

    Publisher: Canadian Investor Magazine
    Author: Rochelle Emnance


    2012, July 30

    Feds back local diabetes discovery

    Publisher: London Free Press
    Author: Norman De Bono

    2012, July 30

    Federal program pumps $3 million into new, London business

    Publisher: The London Free Press

    Author: Norman De Bono

    2010 July 10

    Canada's economic action plan supports business innovators

    Publisher: Federal Economic Development Agency for Southern Ontario


    2007, February 20

    "Transplanted cells may protect against diabetes without forced drug use: An interview with Dr. David White"

    Author: Julie Ickes and James Finch

    2006, October 04

    "Sertoli Cells: Mother nature's anti-rejection drug"

    Author: James Finch

    2006, August 24

    "Mass marketing diabetes reversal; novel xeno-transplants may offer new hope for type 1 diabetics"

    Author: James Finch

    Presentation and Video

    May 03, 2018

    Corporate Presentation

    April 2018

    March 29, 2018

    2018 Financial Report - 1st Quarter

    March 29, 2018

    2018 Management Discussion & Analysis (MD&A) - 1st Quarter

    December 11, 2017

    Clearance by FDA of Sernova's US IND

    Conference call audio recording

    September 11, 2017

    Sernova Fact Sheet

    Subscribe to Sernova News